Plain-English translation of NCT07908979 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
RETAIN-3 is testing whether a personalized approach using and can help treat muscle-invasive bladder cancer while preserving your bladder. After you receive the initial medication, doctors will use blood tests and imaging to see how well it's working. Based on those results, your treatment plan will be tailored specifically to you—which might mean continued medication, close monitoring, additional chemotherapy with radiation, or surgery.
Muscle-invasive bladder cancer traditionally requires removing the entire bladder, which significantly impacts quality of life. This trial explores whether blood biomarkers and imaging can reliably identify patients who can be safely treated without surgery, potentially offering a life-changing alternative for some people.
You likely qualify if…
You likely don't qualify if…
You'll start by receiving the medication combination for 3 cycles, with regular clinic visits for monitoring. After that, your doctors will perform imaging scans and blood tests to see how your cancer has responded. Depending on those results, you may continue with more medication cycles, switch to a maintenance approach with close surveillance, or proceed to other definitive treatments. The trial involves multiple visits over several months, blood draws, and imaging tests at key timepoints.
AI-generated summary from trial data · Nov 6, 2026 · Not medical advice
United States